Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion type Assertion NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_head.
- NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion description "[A panel of seven human EGFR wild-type NSCLC cell lines was characterized for their sensitivity to sequential treatment with cisplatin and erlotinib, and the results were correlated with CHFR.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_provenance.
- NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion evidence source_evidence_literature NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_provenance.
- NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion SIO_000772 20705357 NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_provenance.
- NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion wasDerivedFrom befree-20150227 NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_provenance.
- NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_assertion wasGeneratedBy ECO_0000203 NP920658.RAzrhGbFXq7zecni75CX8leqDhAbWSqf2-HHF2QBgImjQ130_provenance.